• Something wrong with this record ?

Neurofilament heavy chain and chitinase 3-like 1 as markers for monitoring therapeutic response in multiple sclerosis

P. Kusnierova, KZ. Revendova, K. Karasova, D. Zeman, R. Bunganic, P. Hradilek, O. Volny, A. Ganesh, I. Kovacova, D. Stejskal

. 2024 ; 91 (-) : 105915. [pub] 20241002

Language English Country Netherlands

Document type Journal Article, Observational Study

Persistent link   https://www.medvik.cz/link/bmc25003608

AIMS: The aim of this study was to evaluate the association of serum neurofilament heavy chain (sNfH) and chitinase 3-like 1 (sCHI3L1) with treatment response and disease activity in multiple sclerosis (MS). METHODS: This single-center, prospective, observational cohort study was conducted at the MS Centre, University Hospital Ostrava, Czech Republic, from May 2020 to August 2023. sNfH and sCHI3L1 were determined using ELISA. A mixed-effects linear model with a log-transformed outcome variable was applied. RESULTS: We analyzed 459 samples from 57 people with MS. Patients were sampled an average of 8.05 times during 21.9 months of follow-up. Those experiencing a relapse at sampling had a sNfH concentration 50 % higher than those in remission (exp(β) 1.5, 95 % CI 1.15-1.96). A longer duration of treatment was associated with lower sNfH (exp(β) 0.95, 95 % CI 0.94-0.96). Patients switched from low- to high-efficacy disease-modifying therapies (DMTs) had higher sNfH than patients treated with low-efficacy DMTs only (exp(β) 1.95, 95 % CI 1.35-2.81). Higher sCHI3L1 was associated with older age (exp(β) 1.01, 95 % CI 1.00-1.02) and longer DMT use (exp(β) 1.01, 95 % CI 1.00-1.02). sCHI3L1 values were not associated with relapse at the time of sampling, renal function, sex, or type of DMT. CONCLUSION: In contrast to sCHI3L1, sNfH may be a potential biomarker for monitoring treatment response and confirming clinical relapse in MS. Further research is needed to determine the long-term dynamics of sNfH and develop related treatment strategies.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003608
003      
CZ-PrNML
005      
20250206104441.0
007      
ta
008      
250121e20241002ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.msard.2024.105915 $2 doi
035    __
$a (PubMed)39383686
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Kusnierova, P $u University Hospital Ostrava, Institute of Laboratory Medicine, Department of Clinical Biochemistry, Ostrava, Czech Republic; University of Ostrava, Institute of Laboratory Medicine, Ostrava, Czech Republic
245    10
$a Neurofilament heavy chain and chitinase 3-like 1 as markers for monitoring therapeutic response in multiple sclerosis / $c P. Kusnierova, KZ. Revendova, K. Karasova, D. Zeman, R. Bunganic, P. Hradilek, O. Volny, A. Ganesh, I. Kovacova, D. Stejskal
520    9_
$a AIMS: The aim of this study was to evaluate the association of serum neurofilament heavy chain (sNfH) and chitinase 3-like 1 (sCHI3L1) with treatment response and disease activity in multiple sclerosis (MS). METHODS: This single-center, prospective, observational cohort study was conducted at the MS Centre, University Hospital Ostrava, Czech Republic, from May 2020 to August 2023. sNfH and sCHI3L1 were determined using ELISA. A mixed-effects linear model with a log-transformed outcome variable was applied. RESULTS: We analyzed 459 samples from 57 people with MS. Patients were sampled an average of 8.05 times during 21.9 months of follow-up. Those experiencing a relapse at sampling had a sNfH concentration 50 % higher than those in remission (exp(β) 1.5, 95 % CI 1.15-1.96). A longer duration of treatment was associated with lower sNfH (exp(β) 0.95, 95 % CI 0.94-0.96). Patients switched from low- to high-efficacy disease-modifying therapies (DMTs) had higher sNfH than patients treated with low-efficacy DMTs only (exp(β) 1.95, 95 % CI 1.35-2.81). Higher sCHI3L1 was associated with older age (exp(β) 1.01, 95 % CI 1.00-1.02) and longer DMT use (exp(β) 1.01, 95 % CI 1.00-1.02). sCHI3L1 values were not associated with relapse at the time of sampling, renal function, sex, or type of DMT. CONCLUSION: In contrast to sCHI3L1, sNfH may be a potential biomarker for monitoring treatment response and confirming clinical relapse in MS. Further research is needed to determine the long-term dynamics of sNfH and develop related treatment strategies.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a dospělí $7 D000328
650    12
$a neurofilamentové proteiny $x krev $7 D016900
650    12
$a protein CHI3L1 $x krev $7 D000071451
650    12
$a biologické markery $x krev $7 D015415
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a roztroušená skleróza $x krev $x farmakoterapie $7 D009103
650    _2
$a imunologické faktory $x aplikace a dávkování $x farmakologie $7 D007155
650    _2
$a následné studie $7 D005500
650    _2
$a hodnocení výsledků zdravotní péče $7 D017063
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Revendova, K Zondra $u University Hospital Ostrava, Department of Neurology, Ostrava, Czech Republic; University of Ostrava, Department of Clinical Neurosciences, Ostrava, Czech Republic. Electronic address: kamila.revendova@fno.cz
700    1_
$a Karasova, K $u University of Ostrava, Department of Clinical Neurosciences, Ostrava, Czech Republic
700    1_
$a Zeman, D $u University Hospital Ostrava, Institute of Laboratory Medicine, Department of Clinical Biochemistry, Ostrava, Czech Republic; University of Ostrava, Institute of Laboratory Medicine, Ostrava, Czech Republic
700    1_
$a Bunganic, R $u University Hospital Ostrava, Department of Neurology, Ostrava, Czech Republic; University of Ostrava, Department of Clinical Neurosciences, Ostrava, Czech Republic
700    1_
$a Hradilek, P $u University Hospital Ostrava, Department of Neurology, Ostrava, Czech Republic; University of Ostrava, Department of Clinical Neurosciences, Ostrava, Czech Republic
700    1_
$a Volny, O $u University Hospital Ostrava, Department of Neurology, Ostrava, Czech Republic; University of Ostrava, Department of Clinical Neurosciences, Ostrava, Czech Republic
700    1_
$a Ganesh, A $u University of Calgary Cumming School of Medicine, the Hotchkiss Brain Institute and the O'Brien Institute for Public Health, Departments of Clinical Neurosciences and Community Health Sciences, Calgary, Canada
700    1_
$a Kovacova, I $u University Hospital Ostrava, Department of Hematooncology, Ostrava, Czech Republic
700    1_
$a Stejskal, D $u University Hospital Ostrava, Institute of Laboratory Medicine, Department of Clinical Biochemistry, Ostrava, Czech Republic; University of Ostrava, Institute of Laboratory Medicine, Ostrava, Czech Republic
773    0_
$w MED00188780 $t Multiple sclerosis and related disorders $x 2211-0356 $g Roč. 91 (20241002), s. 105915
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39383686 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104436 $b ABA008
999    __
$a ok $b bmc $g 2263389 $s 1239615
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 91 $c - $d 105915 $e 20241002 $i 2211-0356 $m Multiple sclerosis and related disorders $n Mult Scler Relat Disord $x MED00188780
LZP    __
$a Pubmed-20250121

Find record

Citation metrics

Archiving options